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Hendra virus (HeV) and Nipah virus (NiV) are deadly zoonotic viruses for which no vaccines or therapeutics are licensed
for human use. Henipavirus infection causes severe respiratory illness and encephalitis. Although the exact route of trans-
mission in human is unknown, epidemiological studies and in vivo studies suggest that the respiratory tract is important
for virus replication. However, the target cells in the respiratory tract are unknown, as are the mechanisms by which heni-
paviruses can cause disease. In this study, we characterized henipavirus pathogenesis using primary cells derived from the
human respiratory tract. The growth kinetics of NiV-Malaysia, NiV-Bangladesh, and HeV were determined in bronchial/
tracheal epithelial cells (NHBE) and small airway epithelial cells (SAEC). In addition, host responses to infection were as-
sessed by gene expression analysis and immunoassays. Viruses replicated efficiently in both cell types and induced large
syncytia. The host response to henipavirus infection in NHBE and SAEC highlighted a difference in the inflammatory re-
sponse between HeV and NiV strains as well as intrinsic differences in the ability to mount an inflammatory response be-
tween NHBE and SAEC. These responses were highest during HeV infection in SAEC, as characterized by the levels of key
cytokines (interleukin 6 [IL-6], IL-8, IL-1, monocyte chemoattractant protein 1 [MCP-1], and colony-stimulating factors)
responsible for immune cell recruitment. Finally, we identified virus strain-dependent variability in type I interferon an-
tagonism in NHBE and SAEC: NiV-Malaysia counteracted this pathway more efficiently than NiV-Bangladesh and HeV.
These results provide crucial new information in the understanding of henipavirus pathogenesis in the human respiratory
tract at an early stage of infection.
Nipah (NiV) and Hendra virus (HeV) are emerging zoonoticpathogens of the family Paramyxoviridae and are classified in
the genus Henipavirus (1). NiV and HeV both cause severe and
often fatal respiratory disease and/or encephalitis in animals and
humans. HeV was first isolated during an outbreak of respiratory
and neurologic disease in horses and humans in Australia in 1994
(2–5). To date, a total of 5 outbreaks of HeV involving human
cases have been reported in Australia, and 7 human cases with
a case fatality rate of 57%have been identified (6). The first human
cases ofNiV infectionwere identified during an outbreak of severe
febrile encephalitis inMalaysia and Singapore in 1998-1999 (7, 8).
Several other outbreaks have occurred thereafter in Bangladesh
and India almost yearly since 2001 (6, 9, 10), with the last outbreak
reported in Bangladesh in 2012 (11). NiV strains from Malaysia
(M) and Bangladesh (B) are genetically distinct based on phylo-
genic analyses using amino acid sequences (6, 12). To date, NiV
has been responsible for more than 500 human cases, with mor-
tality rates ranging from 40% (inMalaysia) (13) to 100% (in Ban-
gladesh and India) (6, 11, 14). The natural hosts of henipaviruses
are fruit bats (Pteropus species) (15–17), and transmission of these
viruses from bats to humans may be direct or via an intermediate
host like horses or pigs for HeV and NiV transmission, respec-
tively (2, 15, 18–23). Interestingly, respiratory symptoms such as
cough and difficulty breathing were reported for about 70% of
NiV-B-infected and less than 30% of NiV-M-infected patients
(24). In addition, in recent outbreaks, a high incidence of person-
to-person transmission has been reported in Bangladesh and In-
dia (9, 25, 26) as opposed to the outbreaks of NiV inMalaysia and
HeV in Australia, suggesting differences in host-virus interactions
between genetically distinct henipaviruses.
The main target cells during the late stage of henipavirus
infection in humans are endothelial cells of blood vessels, re-
sulting in vasculitis, vasculitis-induced thrombosis, and vascu-
lar microinfarction in the central nervous system (CNS) but
also in other organs such as the lungs, spleen, and kidneys
(27–29). The infection also reaches the CNS parenchymal cells,
which all together play an important role in the pathogenicity
of henipaviruses (27, 30).
Although the exact route of infection in humans is unknown,
previous studies in several laboratory animal models reported an
efficient infection through intranasal challenge (31–35), suggest-
ing that the respiratory tract is one of the first targets of virus
replication. In addition, both NiV and HeV have been isolated
from oropharyngeal and respiratory secretions from humans and
animals (36–38), which emphasizes the importance of the respi-
ratory tract in virus replication and potential transmission. In
hamsters, NiV infection of the respiratory tract is initiated in the
trachea and progresses down the respiratory tract, infecting the
bronchial epithelium and finally causing severe hemorrhagic
pneumonia, including the characteristic syncytium formation in
the pulmonary endothelium. In contrast, HeV infection is initi-
ated primarily in the small airways of the lungs and not in the
trachea or bronchi (34). In humans, henipavirus infection is char-
acterized by influenza-like illness, which can progress to pneumo-
nia (8, 13, 23, 39, 40) or acute respiratory distress syndrome
(ARDS) as characterized in some cases of NiV-B infection (10).
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Interestingly, while limited data are available on the histopathol-
ogy of the lungs of henipavirus cases, changes in the respiratory
tract in NiV-M-infected patients include hemorrhage, necrosis,
and inflammation in the epitheliumof the small airways but not in
the bronchi (29), similar to observations in hamsters (34) and
nonhuman primates (33). Finally, lesions and inflammation were
reported to occur in the small airways of HeV-infected patients
(23, 28, 40); no information is available about the histopatholog-
ical changes in the respiratory tract of NiV-B-infected patients.
The specific sites of henipavirus infection in the human respira-
tory tract are still unknown, as is the mechanism by which these
viruses can cause disease.
We hypothesize that the human immune response to henipa-
virus infection at an early step of infection can determine the clin-
ical outcome, explain how the virus can disseminate throughout
the host, and affect person-to-person transmission. To gain fur-
ther insight into the early steps of infection, we conducted the first
characterization of NiV and HeV infection of the human respira-
tory tract using primary human epithelial cells derived from the
bronchi (bronchial/tracheal epithelial cells [NHBE]) and the
small airways (small airway epithelial cells [SAEC]). Our results
showed that the replication kinetics of genetically distinctNiV and
HeV strains are efficient in both cell types and result in a differen-
tial innate immune response depending on the virus strain and the
cell origin. Finally, we demonstrate a virus strain-dependent vari-
ability in type I interferon (IFN) signaling that seems independent
of the origin of cells from the human respiratory tract.
MATERIALS AND METHODS
Viruses and cells. NiV-Malaysia (NiV-M), NiV-Bangladesh (NiV-B),
and HeV were kindly provided by the Special Pathogens Branch of the
Centers for Disease Control and Prevention (Atlanta, GA). The viruses
were propagated on Vero cells (CCL-81; ATCC) in Dulbecco’s modified
Eagle’s mediumwith 400 mM L-glutamine, 4,500 mg/liter of glucose, and
sodium pyruvate (Thermo Scientific, Logan, UT) and supplemented with
10% fetal bovine serum, 100 U/ml of penicillin, and 0.1 mg of streptomy-
cin (Sigma-Aldrich, St. Louis, MO) at 37°C and 5% CO2. Cells were
seeded in 96-well plates for virus titration.
NHBE derived from the bronchial tube and normal SAEC derived
from the distal airspace were obtained with the Clonetics Bronchial/Tra-
cheal Epithelial Cell System and the Clonetics Normal Human Small Air-
way Epithelial Cell System (Clonetics, San Diego, CA), respectively.
Monolayers of undifferentiated NHBE and SAEC were cultured in 150-
cm2 flasks for 8 days (37°C and 5% CO2) with a bronchial epithelial cell
basal medium supplied with growth factors in the BEGM BulletKit and
with an SAEC basal medium supplied with growth factors in the SAGM
BulletKit, respectively. All NHBE and SAEC infections were performed at
a multiplicity of infection (MOI) of 5 for 1 h to ensure synchronous
infection. Cells were then rinsed three times with 1 phosphate-buffered
saline (PBS), and appropriate mediumwas added. NHBE and SAECwere
seeded in 6-well plates at 1 106 cells/well (each condition performed in
triplicate) the day prior to infection for virus replication, gene expression,
and cytokine and chemokine quantification. NHBE and SAEC were
seeded in 12-well plates at 3.5 105 cells/well (each condition performed
in triplicate) the day prior to infection for the quantification of Stat1 and
phospho-Stat1 (p-Stat1) by Western blotting.
Viruses were titrated onVero cells in 96-well plates using 10-fold virus
dilutions in triplicate. Virus titer was expressed as median 50% tissue
culture infective dose (TCID50)/ml using the method of Reed and
Muench (41). All work with live viruses was performed in Galveston Na-
tional Laboratory Level 4 (biosafety level 4 [BSL4]) at the University of
Texas Medical Branch.
Gene expression analysis. Total cellular RNA fromNHBE and SAEC
was extracted at 24 h postinfection (p.i.) in triplicate using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s recommen-
dations. RNA was quantified using a NanoDrop ND-1000 (NanoDrop
Technologies, Wilmington, DE) and RNA integrity assessed by visualiza-
tion of 18S and 28S RNA bands using an Agilent BioAnalyzer 2100 (Agi-
lent Technologies, Santa Clara, CA). Total RNA extracted from the sam-
ples was processed using the RNA labeling protocol described by Ambion
(MessageAmp aRNA kit instruction manual) and hybridized to Af-
fymetrix Gene Chips (HGU133 Plus 2.0 arrays, total genome). Data qual-
ity was assessed by applying the quality matrix generated by the Af-
fymetrix GeneChip Command Console (AGCC) software. The resulting
data were analyzed with Partek Genomics Suite (Partek, St. Louis, MO).
Principal-component analysis as a quality assurance measure was per-
formed. The raw data were normalized through robust multichip averag-
ing upon import to Partek Genomics Suite. An analysis of variance
(ANOVA) was carried out and a false discovery rate (FDR) applied to
reduce the occurrence of false positives. The data set was filtered for a P
value of 0.05 and a cutoff of 2.00, resulting in the final list of differen-
tially expressed genes. Ingenuity Pathway Analysis (IPA) software and
iReport (Ingenuity Systems, RedwoodCity, CA)were thenused to analyze
and interpret data. The analyses of the most significant biological func-
tional groups and canonical pathways affected per condition were per-
formed using an uncorrected P value calculation method [right-tailed
Fisher exact method, P  0.05 or log(P value)  1.3]. A ratio (r) ac-
counting for the number of overlapping genes from a particular pathway
was also introduced to help in the analyses of filtered data.
Real-time SYBR green qPCR assay design. Real-time quantitative
PCR (qPCR) assays were designed from the coding sequence (CDS) of the
gene of interest (NCBI) and exon-exon junctions mapped via BLAT (42).
Whenever possible, at least one of the two PCR primers was designed to
transcend an exon-intron junction in order to reduce the impact of
potential genomic DNA amplification in the surveyed RNA samples.
Primers were designed with Primer Express 2.0 (Applied Biosystems,
Foster City, CA) using default settings (primer melting temperature
[Tm] 58°C to 60°C, GC content 30 to 80%, and amplicon length 90
to 150 nucleotides). Primers were synthesized (IDT, San Jose, CA) and
reconstituted to a final concentration of 100 M (master stock) prior to
dilution to a working stock of 6 M. Primer sequences used for quantify-
ing the gene expression levels were as follows: Stat1 forward (for), GAAA
GTATTACTCCAGGCCAAAGG; Stat1 reverse (rev), TGTAAACATGTC
ACTCTTCTGTGTTCA; CCL5 for, TCTACACCAGTGGCAAGTGCTC;
CCL5 rev, CCCGAACCCATTTCTTCTCTG; CXCL10 for, CTTTCTGA
CTCTAAGTGGCATTCAAG; CXCL10 rev, TGGATTAACAGGTTGAT
TACTAATGCTG; CXCL11 for, CCTTGGCTGTGATATTGTGTGC;
CXCL11 rev, GAGGCTTTCTCAATATCTGCCAC; IFIT1 for, CTGGGT
ATGCGATCTCTGCC; IFIT1 rev, TTAAGCGGACAGCCTGCC; IFNB1
for, GCAGTTCCAGAAGGAGGACG; IFNB1 rev, TCCAGCCAGTGCTA
GATGAATC; IL-8 for, CAGCCTTCCTGATTTCTGCAG; IL-8 rev, AGG
TTTGGAGTATGTCTTTATGCACTG; ISG15 for, ATCTTTGCCAGTA
CAGGAGCTTG; ISG15 rev, GACACCTGGAATTCGTTGCC;MX-1 for,
GGAGGAGATCTTTCAGCACCTG; MX-1 rev, GCCGTACGTCTGGA
GCATG; ephrin-B2 for, TCCAGAACTAGAAGCTGGTACAAATG; eph-
rin-B2 rev, GAATGTCCGGCGCTGTTG; ephrin-B3 for, GTCTGAAAT
GCCCATGGAAAGA; and ephrin-B3 rev, GAGGTTGCATTGCTGG
TGG. Reverse transcription was performed on 1 g of total RNA
(previously assayed via Affymetrix GeneChip) with random primers, uti-
lizing TaqMan reverse transcription reagents (Applied Biosystems) as rec-
ommended by themanufacturer. Although themass of input RNA should
not be utilized for normalization purposes, amounts of input RNA to be
assayed should be equivalent. The reverse transcription reaction was used
as the template for the subsequent PCR, consisting of FastStart Universal
SYBR green PCR master mix (ROX) (Roche, Indianapolis, IN), 1 l of
template cDNA, and assay primers (300 nMfinal concentration) in a total
reaction volume of 25 l. Thermal cycling was carried out with an ABI
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Prism 7500 sequence detection system (Life Technologies, Carlsbad, CA)
under factory defaults (50°C for 2 min, 95°C for 10 min, and 40 cycles at
95°C for 15 s and 60°C for 1 min). Threshold cycle (CT) numbers were
defined as fluorescence values, generated by SYBR green binding to dou-
ble-stranded PCR products, exceeding baseline. Relative transcript levels
were quantified as a comparison of measured CT values for each reaction
to a designated control via the CT method (43). In order to normalize
for template input, 18S rRNA (endogenous control) transcript levels were
measured for each sample and utilized in these calculations. A Student t
test was applied to 18S rRNA CT values to rule out any change in expres-
sion of the endogenous control due to treatment. Fold change values were
calculated as a log 2 ratio of theCT averages of the biological replicates.
Milliplex analysis. Cytokine and chemokine concentrations in the
supernatants of henipavirus-infected NHBE and SAEC were determined
using a Milliplex Human Cytokine PREMIXED 28 Plex immunoassay kit
(Millipore, Billerica, MA). Prior to analysis, samples were inactivated on
dry ice by gamma radiation (5 megarads). The assay was performed ac-
cording to the manufacturer’s instructions. The human cytokine stan-
dardswere prepared usingNHBE and SAECmedia. The concentrations of
28 cytokines {epidermal growth factor (EGF), granulocyte colony-stimu-
lating factor (G-CSF), granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), IFN-2, IFN-	, interleukin 1 (IL-1), IL-1
, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15,
IL-17A, chemokine ligand 3-like 1 (CCL3L1 or MIP-1), chemokine li-
gand 4 (CCL4 or MIP-1
), chemokine ligand 10 (IP-10 or CXCL10),
chemokine ligand 11 (CCL11 or eotaxin), chemokine ligand 13 (CCL13
or monocyte chemoattractant protein 1 [MCP-1]), tumor necrosis factor
alpha (TNF-), lymphotoxin alpha (TNF-
), and vascular endothelial
growth factor A (VEGF)} were quantified.
Western blot experiments. To characterize the levels of IFN antago-
nism in henipavirus-infectedNHBE and SAEC, 1,000 IU/ml of IFN-
was
added for 1 h to stimulate cells at 12, 18, and 24 h postinfection. The cell
lysates were then harvested, and the levels of expression of signal trans-
ducer and activator of transcription 1 (Stat1) and phosphorylated Stat1
(p-Stat1) were quantified by Western blotting. Samples were inactivated
by lysis in 2 SDS lysing buffer (0.5 M Tris-HCl at pH 6.8, 20% glycerol,
10% [wt/vol] SDS, 0.1% [wt/vol] bromophenol blue, and 2-mercaptoeth-
anol at a 5.0% final concentration) and heating for 5 min at 100°C. Pro-
teins were run on SDS-PAGE, transferred to polyvinylidene difluoride
membranes (Bio-Rad, Hercules, CA), and blocked in a Superblock buffer
(Thermo Scientific, Logan, UT) before immunodetection. A rabbit poly-
clonal IgG was used for Stat1 p84/p91 detection (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and for p-Stat1(Y701) p84/p91 detection (Cell Signal-
ing Technology, Danvers,MA). A sheep polyclonal antibody to rabbit IgG
conjugated to horseradish peroxidase (HRP) was used as a secondary
antibody for Stat1 and p-Stat1 detection. Beta-actin was used as loading
control and was detected using a mouse monoclonal antibody directly
conjugated to HRP (Abcam, Cambridge, MA). Stat1 and p-Stat1 expres-
sion levels were quantified with Quantity One Software during henipavi-
rus infection at 12, 18, and 24 h p.i. (experiment performed in triplicate).
The Stat1 and p-Stat1 intensities were corrected by dividing by the actin
intensity. The pStat1/Stat1 ratio was then generated using the p-Stat1 and
Stat1 corrected intensities.
Statistical analyses. Comparisons of virus replication levels, gene ex-
pression fold changes by qPCR assay, concentrations of cytokines and
chemokines, and pStat1/Stat1 ratioswere subjected to a repeated-measure
one-way ANOVA in which the virus strain used (or control versus virus)
was the independent variable. When the ANOVAs revealed a significant
main effect, a post hoc test such as Bonferroni’s multiple-comparison test
was used to determine whether treatmentmeans were significantly differ-
ent from one another. Comparison of NiV-M or NiV-B or HeV replica-
tion levels in cells left untreated or treated with IFN was performed using
the paired t test. All data are presented in figures as means  standard
deviations (SD).
RESULTS
Primary human epithelial cells derived from the bronchi and
the small airway are highly susceptible to henipavirus infection.
Epithelial cells derived from the bronchi (NHBE) and the small
airways (SAEC) of the human respiratory tract were investigated
as potential initial sites of henipavirus replication. Both cell types
expressed the henipavirus receptors ephrin-B2 and -B3, suggest-
ing that they are permissive for infection. Gene expression of eph-
rin-B2 in SAEC was 2-fold higher than in NHBE. In contrast,
ephrin-B3 gene expression in NHBE was 5-fold higher than in
SAEC. Upon infection, both NHBE and SAEC were highly per-
missive to NiV-M, NiV-B, and HeV replication. Using anMOI of
5 to synchronize infection, the first cytopathic effect (CPE), char-
acterized by syncytium formation, in infected NHBE and SAEC
was observed as early as 12 to 18 h postinfection (p.i.), indepen-
dent of the virus strain. NiV-infected cells showed extensive syn-
cytium formation compared to that of HeV-infected cells at 24 h
p.i. (Fig. 1A and B). NHBE and SAEC cultures infectedwith any of
the henipavirus strains showed completeCPEby 48 hp.i.HeV and
NiV replication was able to reach a high titer (greater than 106.5
TCID50s/ml) in both NHBE and SAEC at 32 h p.i. No significant
differences between replication of the two NiV strains and HeV
were observed in NHBE at any time point up to 48 h p.i. (Fig. 1C).
In contrast, in SAEC,HeV replicated significantly faster up to 18 h
p.i. (105.2 TCID50s/ml) than did NiV-M and NiV-B (10
3.9 and
103.8 TCID50s/ml, respectively; P 0.05).
Study of gene expression in henipavirus-infected NHBE and
SAEC. Characterization of the global henipavirus-host interactions
inSAECandNHBEwasperformedbymicroarrayanalysis at24hp.i.,
a time point at which virus titers were identical for all three viruses
(Fig.1CandD) anddifferential expressionof host immune response-
related genes, such as those for IL-6,MX-1, andCXCL10,washighest
based on preliminary data obtained by real-time quantitative reverse
transcription-PCR (qRT-PCR) assays (data not shown). A global
analysis of the data bymicroarray showed thatNiV-M induced larger
numbers of differentially expressed genes inNHBE and SAEC (2,540
and 2,223, respectively) than did NiV-B (1,817 and 1,836, respec-
tively) or HeV (2,075 and 1,642, respectively) (Fig. 2A). More than
half of thosedifferentially expressedgenes in infectedNHBEorSAEC
were common to all 3 virus strains (Fig. 2B).
To gain more insight into the immune response against henipa-
virus infection in NHBE and SAEC, the most significant functional
annotationsweredeterminedbyIngenuityPathwayAnalysisusingall
differentially expressed genes per condition (i.e., NiV-MorNiV-Bor
HeV inNHBE or SAEC) (Fig. 3A and B). InNHBE, the data showed
that NiV-M was the only virus that did not affect the expression of
genes related to the antimicrobial response, the cell-mediated im-
mune response, and immune cell trafficking. Also, NiV-M infection
in NHBE affected very few genes from the inflammatory response
compared to NiV-B or HeV (Fig. 3A) but triggered twice more dif-
ferentially expressed genes in the infectious disease group than did
NiV-B infection. In SAEC, NiV-M and NiV-B infection triggered
similar numbers of differentially expressed genes related to the in-
flammatory response, the infectious disease, the cell-mediated im-
mune response, and immune cell trafficking but did not modify the
expression of genes related to the antimicrobial response (Fig. 3B).
Finally, HeV infection triggered at least three times more differen-
tially expressed genes related to the inflammatory response than
NiV-M or NiV-B infection.
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The most significant immune response-related canonical
pathways were then determined using all differentially expressed
genes. In NHBE, the IFN signaling pathway and the pattern rec-
ognition receptors (PRR) pathway, which included Toll-like re-
ceptor signaling and RIG-I-like receptor signaling, were in the top
10 list of the total canonical pathways affected byHeV (Fig. 3C), as
with the IL-6 and IFN signaling pathways in SAEC (Fig. 3D).None
of these pathways in NHBE or SAEC were reported in such a high
rank or could even be considered (P  0.05) using NiV-M or
NiV-B (Fig. 3C andD). Surprisingly, no immune response-related
canonical pathways were observed in the top 10 list of the total
canonical pathways affected byNiV infection inNHBE and SAEC,
with the exception of B cell receptor signaling in NiV-B-infected
NHBE. In addition, the P values associated with IL-6 and -8 sig-
naling during NiV-B infection in NHBE were more significant
than inHeVorNiV-M infection (Fig. 3C). TheP values associated
with IL-6 and -8 signaling were significant inNiV-M infection but
not duringNiV-B infection in SAEC (Fig. 3D). Finally, an analysis
of the differentially expressed genes that were unique toNiV-Mor
NiV-B infection (Fig. 2B) did not show any immune response-
related canonical pathway in either NHBE or SAEC (P  0.05).
However, using HeV, the roles of PRR, IFN signaling, and RIG-I-
like receptors in antiviral innate immunity pathway had signifi-
cant P values in NHBE, as did IFN signaling, IL-6, GM-CSF, PRR
in recognition of viruses, and the IL-17 pathway in SAEC.
Overall, the fold changes for the most upregulated immune
FIG 2 Global gene expression analysis of henipavirus infection in primary
epithelial cells from the respiratory tract. (A) Number of differentially ex-
pressed genes following NiV-M, NiV-B, or HeV infection in NHBE and SAEC
compared to uninfected NHBE or SAEC at 24 h postinfection. Cutoff  2; P
value 0.05 (right-tailed Fisher exact method). (B) Venn diagrams showing
unique and common differentially expressed genes between NiV-M-, NiV-B-,
and HeV-infected cells in NHBE and SAEC.
FIG 1 Primary human epithelial cells from the respiratory tract are highly permissive to henipavirus infection. Cultures of NHBE (A and C) and SAEC (B and
D) cells were infected with NiV-M, NiV-B, or HeV as described inMaterials andMethods. (A and B) Syncytium formation observed at 24 h postinfection. Scale
bar, 10m. The black arrows show syncytia in infected cells. (C and D) Kinetics of henipavirus replication in NHBE (C) and SAEC (D). Results are expressed as
the average of 3 repetitions; error bars represent standard deviations. The horizontal dotted line corresponds to the detection limit. *, P  0.05 by ANOVA
(Bonferroni’s multiple-comparison test).
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response-related genes were higher in SAEC than in NHBE using
the same virus and higher in HeV-infected than in NiV-infected
cells (Table 1). These included chemokines (CCL5, CXCL10, and
CXCL11), interleukins (IL-8 and IL-24A), interferon-induced
proteins (IFIT1, IFIT3, MX-1, IFI6, IFI27, and IFI44L), and IFN-

1. The relative quantifications of a subset of these upregulated
genes in infected NHBE and SAEC (the genes for CCL5, CXCL10,
CXCL11, IFIT1, IL-8, ISG15,MX-1, Stat1, and IFN-
1) were con-
firmed by real-time qPCR assays (Fig. 4), which confirmed the
fold change observed with the microarray data (Table 1).
Cytokine and chemokine production by henipavirus-in-
fectedNHBE and SAEC.The amount of a subset of cytokines and
chemokines produced by henipavirus-infected NHBE and SAEC
was determined to confirm the gene expression results (Fig. 5).
Among a panel of 28 human cytokines and chemokines tested,
only 6 cytokines (G-CSF, GM-CSF, IL-1, IL-6, IL-8, and VEGF)
plus 3 chemokines (CXCL10, MCP-1, and eotaxin) were detected
in the supernatant of NHBE or SAEC at 24 h p.i. Surprisingly,
genes for G-CSF and MCP-1 were not significantly expressed in
themicroarray analysis, while their protein expression levels in the
supernatants of infected NHBE or SAEC were elevated at least
2-fold compared to those in uninfected NHBE or SAEC. This was
also true forGM-CSF inNHBEand for IL-1 in SAEC. Finally, the
quantities of IL-6, IL-8, VEGF, CXCL10, and eotaxin detected in
the supernatant of infected cells were concomitant with their re-
spective gene expression fold changes.
With exception of VEGF, all cytokines and chemokines were
secreted at consistently higher concentrations in the supernatants
of SAEC than in the supernatants of NHBE when the same virus
was used. Surprisingly, no significant difference could be noticed
between NiV-M and NiV-B infection in the supernatant of in-
fected NHBE or SAEC as to the amount of cytokines and chemo-
kines, with the exception of G-CSF and GM-CSF in NHBE (P 
0.05). IL-1 and CXCL10 were significantly higher in the super-
natant of HeV-infected SAEC than in NiV-M- or NiV-B-infected
SAEC (P 0.001). This difference was also noticed in the super-
natant of NHBE with CXCL10 (P  0.001). Conversely,MCP-1
was the only selected chemokine that was at a lower concentration
in the supernatant of HeV-infected SAEC than in the supernatant
of NiV-infected SAEC.
Type I interferon pretreatment of epithelial cells derived
from the bronchi and the small airway can limit henipavirus
replication. Since NiV and HeV have been shown to counteract
the innate immune response and particularly the type I inter-
feron (IFN) response, the effect of IFN treatment on virus rep-
lication in NHBE and SAEC was assessed (Fig. 6). Cells were
treated with 1,000 IU/ml of IFN-
 for 24 h prior to infection.
IFN treatment of NHBE cells resulted in complete inhibition of
NiV-M and NiV-B replication, while low levels of HeV repli-
cation were observed at 32 h p.i. (103.7, 103.5, and 104.8
TCID50s/ml for NiV-M, NiV-B, and HeV, respectively; P 
0.05). The mean virus titer of HeV, NiV-M, and NiV-B at 32 h
p.i. was decreased by 2 to 3 log units (P  0.05) in NHBE
pretreated with IFN. IFN treatment of SAEC delayed both
NiV-M and HeV replication up to 32 h, while NiV-B replica-
tion was observed as early as 24 h p.i. (103.4, 104.7, and 103.6
TCID50s/ml for NiV-M, NiV-B, and HeV, respectively; P 
0.001). The mean virus titer of NiV-M, NiV-B, or HeV at 32 h
p.i. was decreased 1 to 2 log units (P  0.05) in IFN-treated
SAEC.
FIG 3 Gene expression analysis of henipavirus infection in primary epithelial cells from the respiratory tract. Shown are the numbers of differentially expressed
genes in themost significant biological functional groups inNHBE (A) and SAEC (B) at 24 h p.i. and themost significant biological canonical pathways inNHBE
(C) and SAEC (D) at 24 h p.i. The horizontal dashed line represents the false discovery rate, fixed at 5% (P 0.05), with the P value scale on the left y axis. The
ratio (dashed line) is the number of overlapping genes from a particular pathway (scale on the right y axis).
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Characterizationof the interferon immuneresponse inheni-
pavirus-infected NHBE and SAEC. Based on the microarray re-
sults, the interferon signaling pathway was one of the most signif-
icant canonical pathways affected by HeV but not by NiV
infection in both NHBE and SAEC at 24 h p.i. The ability of HeV
and NiV strains to antagonize the interferon signaling was thus
assessed in time by quantifying the amount of phosphorylated
Stat1 (p-Stat1). The levels of beta-actin and Stat1 during henipa-
virus infection in NHBE or SAEC did not significantly change
compared to their respective levels in uninfected cells at 12, 18,
and 24 h p.i. (data not shown). However, henipavirus infection of
NHBE and SAEC resulted in a significant reduction in p-Stat1
induction following a 1-h treatment with 1,000 IU/ml of IFN-

compared to uninfected controls (Fig. 7). No significant differ-
ence in p-Stat1 induction between the 3 virus strains was observed
at 12 h p.i. Interestingly, activation of p-Stat1 was completely
blocked byNiV-Mas early as 18 h p.i. (p-Stat1/Stat1 ratio of 0) but
not by NiV-B or HeV (P  0.001). The quantity of p-Stat1 in
NiV-B- orHeV-infected cells (p-Stat1/Stat1 ratios of 1.0 and 1.1 in
NHBE, respectively, and of 0.8 and 0.9 in SAEC, respectively) was,
however, at that time reduced by about 2 compared to the quan-
tity of p-Stat1 in uninfected NHBE or SAEC (p-Stat1/Stat1 ratios
of 1.9 and 2.1, respectively; P 0.001). Finally, no p-Stat1 could
be detected in any of the henipavirus-infected cells at 24 h p.i.
(p-Stat1/Stat1 ratio of 0), while the ratios in uninfected NHBE or
SAEC were equal to 1.2 and 1.0, respectively (P 0.001).
DISCUSSION
Hendra and Nipah viruses are newly emerging zoonotic viruses
that can cause severe respiratory illness and encephalitis in hu-
mans. Despite intensive studies, little is known about the early
stages of henipavirus infection in the human respiratory tract.
Here we report the establishment and characterization of NiV and
HeV infection in human respiratory epithelium using undifferen-
tiated primary epithelial cell monolayers derived from bronchi
and small airways to study the role of the host responses in patho-
genesis.
The epithelial cells derived from the bronchi (NHBE) and the
small airways (SAEC) of the human respiratory tract were highly
susceptible to NiV and HeV infection, as characterized by high
peak titers and characteristic syncytium formation as early as 12 h
p.i. Although HeV initially replicated faster than NiV-M and
NiV-B in the small airways, all virus strains reached similar peaks
of replication as early as 32 h p.i. in both cell types, making them
likely targets for virus infection during natural infection. The ef-
ficient replication of HeV in bronchus-derived epithelial cells was
surprising, as we previously observed that HeV antigen could not
be detected in the epithelium of trachea and bronchi of infected







NHBE SAEC NHBE SAEC NHBE SAEC
CXCL11 6373 Chemokine (C-X-C motif) ligand 11 27.9 147.6 24.5 114.6 70.4 309.9 Immune response
CTH 1491 Cystathionase (cystathionine gamma-lyase) 17.0 3.8 16.1 2.6 15.7 3.8 Immune response
IL13RA2 3598 Interleukin 13 receptor, alpha 2 13.7 6.8 18.8 12.2 12.7 10.2 Immune response
TSLP 85480 Thymic stromal lymphopoietin 11.3 11.3 13.4 10.1 9.7 12.0 Immune response
ISG15 9636 ISG15 ubiquitin-like modifier 9.1 23.1 8.6 15.3 21.5 27.8 Immune response
ATF3 467 Activating transcription factor 3 4.2 4.0 4.3 4.7 5.2 9.4 Immune response
CXCL2 2920 Chemokine (C-X-C motif) ligand 2 4.1 6.2 10.2 4.6 Immune response
CXCL10 3627 Chemokine (C-X-C motif) ligand 10 3.8 5.0 3.7 3.8 16.4 39.8 Immune response
BIRC3 330 Baculoviral IAP repeat containing 3 3.6 6.8 4.9 11.2 6.0 12.7 Immune response
CCL5 6352 Chemokine (C-C motif) ligand 5 2.5 14.1 2.1 7.5 2.2 17.1 Immune response
IL28A 282616 Interleukin 28A (interferon, lambda 2) 2.4 10.2 Immune response
IFI6 2537 Alpha interferon-inducible protein 6 2.2 5.0 3.9 7.4 20.7 20.3 Immune response
IFI44L 10964 Interferon-induced protein 44-like 2.1 2.0 18.2 10.6 Immune response
IL-8 3576 Interleukin 8 2.0 4.9 2.4 7.4 Immune response
OAS2 4939 2=,5=-Oligoadenylate synthetase 2, 69/71 kDa 2.2 2.6 2.1 9.7 6.3 Immune response
IL-24 11009 Interleukin 24 4.4 10.3 3.7 Immune response
IFI27 3429 Alpha interferon-inducible protein 27 2.4 2.1 3.5 6.6 9.5 Immune response
ISG20 3669 Interferon-stimulated exonuclease gene, 20 kDa 8.1 2.9 7.3 3.3 8.6 Immune response
CXCL3 2921 Chemokine (C-X-C motif) ligand 3 2 3.4 11.5 Immune response
IFIT1 3434 Interferon-induced protein with
tetratricopeptide repeats 1
19.2 131.4 21.5 95.1 42.5 171.0 Interferon signaling
IFIT3 3437 Interferon-induced protein with
tetratricopeptide repeats 3
4.6 17.4 5.1 12.5 11.2 21.7 Interferon signaling
Stat1 6772 Signal transducer and activator of transcription 1 2.5 4.7 2.0 Interferon signaling
OAS1 4938 2=,5=-Oligoadenylate synthetase 1 2.0 4.6 3.2 Interferon signaling
MX1 4599 Myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
2.2 10.4 7.7 Interferon signaling
IFN-
1 3456 Beta 1 interferon 5.3 2.7 2.1 18.3 Interferon signaling
IFI35 3430 Interferon-induced protein 35 2.6 2.6 Interferon signaling
IFITM1 8519 Interferon-induced transmembrane protein 1 2.8 6.8 Interferon signaling
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hamsters, suggesting limited replication in these cells (34). One
explanation is that this observation is species specific. Another key
difference is the fact that we used undifferentiated epithelial cells
in the current study. The conditions present in tissue culture result
in a dedifferentiation and subsequent loss of beating cilia, which
may affect virus entry and replication by an unidentified mecha-
nism. Studies of the role of epithelial differentiation in virus sus-
ceptibility and host responses are ongoing. BothNHBE and SAEC
types have previously been used as in vitromodels to study a vari-
ety of respiratory viruses, including other members of the
Paramyxoviridae family such asmeasles virus and respiratory syn-
cytial virus (44, 45). Overall, these data suggest that human epi-
thelial cells derived from the bronchi and the small airways are
highly relevant to study henipavirus replication in the respiratory
epithelium.
The global analysis of host gene expression revealed twomajor
characteristics. First, henipavirus infection of SAEC resulted in
higher fold changes in host gene expression than obtained with
NHBE, suggesting that epithelial cells derived from different areas
of the human respiratory tract respond differentially to henipavi-
rus infection. This result is in line with the observations that NiV
infection in humans cases, as well as in hamsters, resulted in in-
flammation of the small airways but not the bronchi (29, 34).
Second, infection of NHBE and SAEC with NiV-M, NiV-B, and
HeV resulted in differences in induction of host immune response
between these genetically distinct henipavirus strains. Overall,
host responses were higher in HeV-infected cells than in cells in-
fected with either NiV strain. Specifically, NiV-M infection in
NHBE resulted in differential expression of very few genes related
to the inflammatory response compared to results obtained with
NiV-B or HeV. This is in agreement with the observation that no
inflammation occurred in the epithelium of bronchi in NiV-M-
infected patients (29) and suggests that inflammation may occur
in the bronchi ofNiV-B- orHeV-infected patients even though no
histopathological changes have been reported so far in this area.
Our data clearly showed that key inflammatorymediators, includ-
ing IL-6, IL-8, CXCL10, MCP-1, and CCL5, were highly upregu-
lated in SAEC but not in NHBE infected with henipavirus. Inter-
estingly, HeV induced higher levels of these cytokines and
chemokines than did both NiV strains, with the exception of
MCP-1. IL-6,which is released by epithelial cells andmacrophages
in the respiratory tract, promotes pulmonary inflammation, and
high levels in bronchoalveolar lavage fluid and in serum are cor-
related with severity and mortality of acute respiratory distress
syndrome (ARDS) (46, 47) and with severe disease, including re-
spiratory insufficiency in pandemic H1N1 influenza virus-in-
fected patients (48, 49), respectively. In addition, inhibition of
IL-6 reduces lung injury in mice with acute kidney injury by re-
ducing the levels of IL-8 and neutrophil influx in the lung (50). In
line with the previous statement, IL-8 has also been shown to
control neutrophil-mediated inflammation during rhinovirus in-
fection (51) and to contribute in the pathogenesis of ARDS (52–
55), and it was recently reported at elevated levels in serum of
H5N1-infected patients, especially in those who succumbed to the
FIG 4 Expression of the most upregulated genes of the immune response and interferon signaling in henipavirus-infected NHBE and SAEC. Shown is real-time
qPCR analysis of the expression of CCL5, CXCL10, CXCL11, IFIT1, IL-8, ISG-15, MX-1, IFN-
1, and Stat1 compared to noninfected NHBE or SAEC at 24 h
postinfection. Results are expressed as the averages of 3 repetitions, and bars represent standard deviations. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P
0.0001 (ANOVA; Bonferroni’s multiple-comparison test).
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infection due to respiratory insufficiency (56). Therefore, our data
suggest that IL-6 and IL-8 play important roles in inflammation of
the small airways due to an increased neutrophil influx in the
small airways, as observed in NiV-M-infected dogs (57) and in
HeV-infected swine (58), compared to the bronchi. Chemokines
such as CXCL10 and MCP-1 are macrophage chemoattractants
and, along with CCL5, recruit circulating leukocytes to the in-
flamed tissue. Overexpression of CXCL10 has previously been re-
ported to occur in the lung ofNiV-M- andHeV-infected hamsters
and correlated with the influx of inflammatory cells (34, 59). Its
gene expression level in the lungs of HeV-infected hamsters was
also higher than inNiV-infected hamsters (34), corroborating our
observations in infected NHBE and SAEC. Even though it has
been shown that MCP-1 can be released from bronchial epithe-
lium and contributes to the inflammatory pathology of bronchial
asthma (60), in the current study, MCP-1 was expressed in in-
FIG 5 Quantification of the principal cytokines and chemokines secreted in the supernatants of NHBE and SAEC at 24 h p.i. Cytokines and chemokines were
quantified in infected or uninfected cells as described inMaterials andMethods. Results are expressed as the averages of 3 repetitions, and bars represent standard
deviations. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001 (ANOVA; Bonferroni’s multiple-comparison test.
FIG 6 Type I interferon pretreatment of epithelial cells from the bronchi and the small airways can limit henipavirus replication. Shown are the kinetics of virus
replication in NHBE (A) and SAEC (B) left untreated (solid lines) or pretreated with 1,000 IU/ml of IFN-
1 for 24 h prior to infection (dashed lines). Results are
expressed as the averages of 3 repetitions, with standard deviations. The horizontal dashed line corresponds to the detection limit. The symbols *, #, and 
correspond to significant differences of virus replication levels between untreated and IFN-treated cells using the same strain, using both NiV strains and HeV,
respectively (P 0.05; paired t test).
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fected SAEC only. Similarly, CCL5 gene expression was also
mainly observed in infected SAEC, especially during HeV infec-
tion, which suggests altogether an important role of macrophage
and circulating leukocyte recruitment in the small airways, lead-
ing to a larger inflammatory response than in the bronchi. These
results are in agreement with histopathological changes observed
in the lungs of 2 HeV-infected patients showing either an acute
pulmonary syndrome with intra-alveolar macrophages and other
inflammatory cells in the small airways (28) or focal necrotizing
alveolitis with an influx ofmacrophages as well (40). This is also in
line with the high levels of the inflammatory cytokine IL-1 and
granulocyte-stimulating factor (G-CSF and GM-CSF) secreted in
the supernatant of infected SAEC and, again, mostly during HeV
infection.
In addition to uncovering the role of several key regulators of
inflammation, microarray data also revealed differential gene ex-
pression in the signaling pathway of pattern recognition receptor
(PRR) activation in NiV-B- and HeV-infected cells but not with
NiV-M. The RIG-I-like receptor pathway was activated during
HeV infection, suggesting that type I interferon was expressed in
infected cells. This was confirmed by the increased IFN-
 gene
expression in all infected cells, mainly in SAEC and especially dur-
ing HeV infection, which was in line with the activation of the
IFN-/
 signaling pathway in HeV-infected cells. Consequently,
higher levels of interferon-induced gene expression such as for
IFIT1, IFIT3, MX-1, ISG-15, and IFIT35 were observed in HeV-
infected cells than in NiV-infected cells. Surprisingly, the high
expression of CXCL10 in HeV-infected cells was independent of
gamma interferon induction and could be the result of a direct
viral activation of steps in the interferon pathway (61–63). Inter-
estingly, while NiV and HeV infection resulted in complete inhi-
bition of Stat1 activation at 24 h p.i., NiV-M was more efficient at
blocking Stat1 activation at earlier time points than were NiV-B
and HeV. This result is in line with the differences of NiV-M
replication levels in untreated cellular models and with pretreat-
ment with IFN type I, which were higher than the levels of HeV,
suggesting a more important role of IFN response blocking to
satisfy NiV-M replication. Since growth kinetics for all three vi-
ruses were similar, it is likely that the viral proteins P, V, and W,
which can each inhibit phosphorylation of Stat1 (64–69), differ-
entially affect the IFN pathway dependent on the virus strain. This
differential induction of the IFN response may, in turn, affect
virulence through an unknown mechanism, as suggested for a
recently discovered henipavirus, Cedar virus (70), as well as for
influenza viruses. The nonstructural NS1 protein of influenza vi-
rus is the main viral IFN antagonist, and NS1 proteins of more
virulent strains were recently reported as having a higher inter-
feron type I signaling inhibitory activity in vitro as well as contrib-
uting to a more persistent infection in the upper and lower respi-
ratory tracts of ferrets (71). In outbreaks, the NiV-M strain has
been less virulent than the NiV-B strain despite an increased abil-
ity to block interferon type I signaling in vitro. In various animal
models, such as hamsters, ferrets, and African green monkeys,
HeV has consistently been more virulent than NiV-M and NiV-B
despite being more sensitive to IFN (unpublished data). Interest-
ingly, a NiV-M strain lacking either the C or V protein did not
cause any clinical signs in hamsters, which was possibly due to a
reduced replication ability as observed in vitro (72). These results
suggest that viral proteins with IFN antagonist functions can in-
fluence the virulence, although the exact role of interferon antag-
onism in the pathogenesis of henipaviruses remains unclear.
Finally, the high level of secreted VEGF, as observed in the
supernatant of infected NHBE, may play a role in airway remod-
eling, a phenomenon previously observed during rhinovirus-as-
sociated asthma exacerbations (73). The monolayer NHBE used
in this study define a simplified model but if relevant in vivo, the
VEGF overexpression might affect the subjacent endothelial cells
and lead to vascular leakage and increased permeability (74). This
is part of ongoing studies using a more complex in vitro model
including both epithelial and endothelial cells. To our knowledge,
there is no study reporting a role for VEGF during henipavirus
infection or a remodeling of the respiratory tract in infected ani-
mals and in human cases. Its function in the respiratory tract, and
particularly in the bronchi, in facilitating henipavirus dissemina-
tion into the vascular system is still unknown and requires further
investigations.
In conclusion, our data show that henipaviruses are able to
efficiently replicate in epithelial cells derived from the bronchi and
the small airways of the human respiratory tract. Infection of these
cells results in a higher inflammatory response in SAEC than in
NHBE, especially during HeV infection, including key inflamma-
tory mediators: IL-6, IL-8, IL-1, MCP-1, G-CSF, GM-CSF, and
FIG 7 Expression and activation of Stat1 during henipavirus infection in human primary epithelial cells from the respiratory tract. Prior to protein harvesting,
all cells were treated with 1,000 IU/ml of IFN-
1 for 1 h (seeMaterials andMethods). The experiment was performed in triplicate. The Stat1 and phosphorylated
Stat1 were detected by Western blotting, and the intensities were corrected using the beta-actin loading control. The p-Stat1/Stat1 ratios in uninfected and
infected cells are plotted in panels A and B for NHBE and SAEC, respectively. *, P  0.05; **, P  0.01; ***, P  0.001 (ANOVA; Bonferroni’s multiple-
comparison test).
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CXCL10. Finally, we demonstrate a virus strain-dependent vari-
ability in type I IFN signaling. This study demonstrates that pri-
mary human epithelial cells derived from the bronchi and the
small airways serve as an important site of HeV and NiV replica-
tion, suggesting that both viruses have the potential for human-
to-human transmission through aerosols. We believe that these
models allow for more detailed studies of the pathogenesis of re-
spiratory disease caused by HeV and NiV infection in humans.
These data provide several target genes and pathways that poten-
tially play roles in henipavirus pathogenesis which will be valuable
as candidates for future studies of the mechanism of henipavirus
pathogenesis and as potential targets for treatment.
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